Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors

NCT06060613 is registered in ClinicalTrials.gov with Obsidian Therapeutics, Inc. as lead sponsor.

NCT NCT06060613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06060613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors
Lead sponsor
Obsidian Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 25, 2023
Completion date
June 30, 2029
Enrollment
254 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, melanoma, metastatic lung cancer, metastatic melanoma, metastatic non small cell lung cancer, non small cell lung cancer, tumor skin